What it is
AOD-9604 is a synthetic, cyclic 16-amino-acid peptide based on the C-terminal region of human growth hormone. It was developed as an obesity drug intended to retain a fat-metabolism signal without reproducing the broader growth-hormone and IGF-1 effects of full-length HGH. It is a growth-hormone fragment, not a growth-hormone secretagogue.
Why it attracts bodybuilders
The pitch is unusually clean: increase lipolysis, reduce new fat storage, and make cutting easier without stimulants, appetite suppression, or the growth and glucose effects associated with HGH. It is also marketed for stubborn abdominal fat, localized fat loss, lean-mass preservation, and sometimes joint repair. Those claims run well ahead of the human evidence.
The animal mechanism
Obese-rat and obese-mouse studies reported less weight gain, greater fat oxidation, and increased lipolytic sensitivity. One frequently cited mouse experiment found that chronic effects depended on the beta-3 adrenergic pathway and coincided with increased beta-3 receptor expression. The authors specifically concluded that the effect was not mediated directly through that receptor, which is more cautious than the common claim that AOD-9604 is simply a beta-3 agonist.
The human obesity result
An early 300-person oral study reported a small and non-linear signal, strongest at its lowest tested dose, but the findings were only published as a meeting abstract rather than a complete paper. The larger OPTIONS Phase IIb study enrolled 536 adults and randomized 502 to AOD-9604 or placebo alongside supervised diet and exercise. It found no statistically significant weight-loss difference at 12 or 24 weeks. The sponsor ended development for obesity in 2007 because the result did not support commercial use.
Lipolysis is not fat loss
Mobilizing fatty acids from a fat cell is an intermediate step, not the outcome. Those fatty acids still need to be oxidized rather than stored again, and net fat loss still depends on whole-body energy balance. A plausible cellular mechanism can therefore be real while producing no meaningful change in body weight or composition. The negative pivotal trial is more informative than the pathway story.
The subcutaneous evidence gap
The historical human program used oral or intravenous AOD-9604. FDA's evidence review found no human exposure, effectiveness, pharmacokinetic, or safety data for the subcutaneous route now promoted in peptide clinics and bodybuilding circles. That means the failed oral program does not prove every injected formulation is inactive, but it also means subcutaneous claims are unvalidated rather than clinically rescued.
No anabolic or spot-reduction evidence
The human safety program did not show an increase in IGF-1, which fits the compound's intended separation from full-length HGH. There are no controlled human data showing muscle gain, lean-mass preservation, strength improvement, or preferential loss of fat near an injection site. Calling it an HGH fragment does not make it an anabolic intervention.
The cartilage claim
The main cartilage result came from 32 rabbits with chemically induced knee osteoarthritis. Ultrasound-guided injections directly into the joint improved morphology and histology, with the AOD-9604-plus-hyaluronic-acid group generally performing best. That does not establish that systemic subcutaneous use repairs human cartilage, treats joint pain, or improves workout recovery.
Safety and product boundary
A sponsor-funded summary of six oral and intravenous trials covering 893 participants reported broadly placebo-like tolerability, no meaningful IGF-1 or glucose-tolerance change, and no detected anti-AOD-9604 antibodies in the tested samples. The longest obesity exposure was 24 weeks, and those data do not establish long-term or subcutaneous safety. FDA separately flags limited safety information and potential problems with peptide aggregation, immunogenicity, impurities, and active-ingredient characterization in compounded products. Gray-market identity and potency add another uncertainty to any personal result unless independently verified.
AOD-9604 is not part of an FDA-approved drug and is prohibited at all times for tested athletes under the World Anti-Doping Agency's growth-hormone-fragment category.
Sources
- Ng et al., Hormone Research 2000 — metabolic effects in obese Zucker rats.
- Heffernan et al., Endocrinology 2001 — obese-mouse and beta-3-receptor-knockout experiments.
- Stier et al., Journal of Endocrinology and Metabolism 2013 — sponsor-funded pooled human safety report.
- Kwon and Park, Annals of Clinical & Laboratory Science 2015 — rabbit osteoarthritis experiment.
- FDA AOD-9604 evidence review, 2024 — human efficacy, route limitations, safety, and compounding assessment.
- FDA compounding-risk notice — current safety and product-quality concerns.
- WADA Prohibited List — current anti-doping status.